Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Pyruvate anaplerosis is a mechanism of resistance to pharmacological glutaminase inhibition in triple-receptor negative breast cancer

Fig. 1

Breast cancer cell lines display differences in sensitivity to pharmacological glutaminase inhibition depending on culture medium composition. a MDA-MB-231 cells were more sensitive to 3 days CB-839 exposure when assayed in RPMI 1640 + 5% FBS (RPMI 1640) compared with αMEM + 5% FBS (αMEM) or DMEM + 5% FBS (DMEM) (mean ± SEM, n = 2–4, one-way ANOVA). CB-839 (b) or BPTES (c) display more potent IC50 values when assayed in RPMI 1640 + 5% FBS compared with αMEM + 5% FBS in many breast cancer cell lines (mean ± SEM, n = 2–4, unpaired t test)

Back to article page